Nothing said here yet.
to join the conversation.
argenx (ENXTBR:ARGX) has completed its acquisition of Forte Biosciences, adding antibody candidate FB102 to its immunology pipeline. The transaction supports argenx's Vision 2030 plan to broaden its presence in autoimmune disease treatment.
argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte’s Friday closing price.
argenx (ENXTBR:ARGX) is set to consider and discuss the acquisition of Forte Biosciences, Inc. The potential deal would expand argenx's reach in biopharmaceutical research and development.
August 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc.
Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. FBRX saw significant price movement beginning June 29, weeks before the public announcement.
The biopharma sector is in the middle of a transformation in which macroeconomic pressures and policy developments actively dictate corporate dealmaking.
argenx SE has entered into a definitive agreement to acquire Forte Biosciences through a cash tender offer. The boards of both companies have approved the transaction, which is expected to close soon, subject to customary conditions.
The transaction is expected to close in the third quarter of 2026.
The transaction is expected to close in the third quarter of 2026.
Investor optimism was driven by AI optimism, a multibillion-dollar acquisition, and strong earnings execution.
Forte Biosciences stock soars on a $2.2 billion takeover proposal from Argenx. But is there any further upside left in FBRX shares? Let’s find out!